Company Overview

Update
Founded:
2002
Headquarters:
Durham, NC
Funding:
$95.20M
Categories:
Biotechnology

Chimerix is a biotechnology company developing therapeutics for antiviral diseases.

Description

Update

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company’s lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug’s antiviral activity in humans.

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral... See More

Current Team (3)

Update

Board Members and Advisors (5)

Update

Funding Rounds (4) - $95.20M

Update

Investors (9)

Update

Offices/Locations (1)

Update
  • Headquarters

    2505 Meridian Parkway

    Suite 340

    Durham, NC 27713

    USA